Smart test could tailor breast cancer treatment and boost quality of life
NCT ID NCT06446882
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether a special test called HER2DX can help doctors choose the best treatment for people with early-stage HER2-positive breast cancer. About 304 participants will be split into two groups: one group gets standard treatment without the test results, and the other gets treatment guided by the test. The goal is to see if using the test leads to better quality of life and less fatigue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY-STAGE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre León Bérard
RECRUITINGLéon, France
-
Complejo Asistencial Universitario de León
RECRUITINGLeón, León, 24008, Spain
-
Gustave Roussy
RECRUITINGParis, France
-
Hanusch Krankenhaus
RECRUITINGVienna, Austria
-
Hospital Clínico Universitario Virgen de Arrixaca
RECRUITINGMurcia, Murcia, 30120, Spain
-
Hospital Clínico Universitario de Santiago
RECRUITINGSantiago de Compostela, La Coruña, 15706, Spain
-
Hospital Universitario Clínico San Cecilio
RECRUITINGGranada, Granada, 18007, Spain
-
Hospital Universitario Ramón y Cajal
RECRUITINGMadrid, Madrid, 28034, Spain
-
Hospital Universitario Sant Joan de Reus
RECRUITINGReus, Tarragona, 42301, Spain
-
Hospital Universitario de Basurto
RECRUITINGBilbao, Vizcaya, 48013, Spain
-
Hospital Universitario de Salamanca
RECRUITINGSalamanca, Spain
-
Institut Paoli Calmettes
RECRUITINGMarseille, France
-
Institut de Cancérologie de Lorraine
RECRUITINGNancy, France
-
Institute Oncology Veneto
RECRUITINGPadova, Italy
-
Instituto Catalán de Oncología (ICO) - Badalona
RECRUITINGBadalona, Spain
-
Instituto Catalán de Oncología (ICO) - Hospitalet
RECRUITINGL'Hospitalet de Llobregat, Barcelona, 08908, Spain
-
Istituto Europeo di Oncologia
RECRUITINGMilan, Italy
-
Klinik Hietzing, Gynäkologische Abteilung - Karl Landsteiner Institut für gyn. Onkologie
RECRUITINGVienna, Austria
-
Klinikum Wels-Grieskirchner
RECRUITINGWels, Austria
-
Lkh Hochsteiermark-Leoben
RECRUITINGLeoben, Austria
-
MUG-Univ.-Klinik für Frauenheilkunde und Geburtshilfe, Klinische Abteilung für Gynäkologie
RECRUITINGGraz, Austria
-
Medizinische Universität Wien, Allg. Gynäkologie und Gyn. Onkologie
RECRUITINGVienna, Austria
-
Oncopole Claudius Regaud, IUCT-Oncopole
RECRUITINGToulouse, France
-
Ordensklinikum Linz, Barmherzige Schwestern, Bhs
RECRUITINGLinz, Austria
-
Polyclinique Bordeaux Nord
RECRUITINGBordeaux, France
-
Sainte-Catherine - Institut du Cancer Avignon-Provence
RECRUITINGAvignon, France
-
Sheba Medical Center
RECRUITINGRamat Gan, Israel
-
Uniklinikum Salzburg
RECRUITINGSalzburg, Austria
-
Universitätsklinikum St.Pölten
RECRUITINGSankt Pölten, Austria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smartwatch could spot nerve damage before it starts
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Six-Gene clue: could a simple test forecast lung spread in breast cancer?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer